Latest Insider Transactions at Rubius Therapeutics, Inc. (RUBY)
This section provides a real-time view of insider transactions for Rubius Therapeutics, Inc. (RUBY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Rubius Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Rubius Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 24
2023
|
Dannielle Appelhans CEO and President |
SELL
Open market or private sale
|
Direct |
10,385
-100.0%
|
$0
$0.13 P/Share
|
|
Feb 01
2023
|
Dannielle Appelhans CEO and President |
SELL
Open market or private sale
|
Direct |
3,878
-27.19%
|
$0
$0.25 P/Share
|
|
Feb 01
2023
|
Pablo J Cagnoni Director |
SELL
Open market or private sale
|
Direct |
8,448
-11.34%
|
$0
$0.25 P/Share
|
|
Jan 31
2023
|
Dannielle Appelhans CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+34.46%
|
-
|
|
Jan 31
2023
|
Laurence A. Turka Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,593
-12.36%
|
$0
$0.24 P/Share
|
|
Jan 31
2023
|
Laurence A. Turka Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,625
+29.13%
|
-
|
|
Jan 31
2023
|
Pablo J Cagnoni Director |
SELL
Open market or private sale
|
Direct |
7,240
-8.85%
|
$0
$0.24 P/Share
|
|
Jan 31
2023
|
Pablo J Cagnoni Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+23.41%
|
-
|
|
Jan 29
2023
|
Laurence A. Turka Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,438
+37.57%
|
-
|
|
Jan 29
2023
|
Pablo J Cagnoni Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,250
+27.24%
|
-
|
|
Aug 10
2022
|
Dannielle Appelhans CEO and President |
SELL
Open market or private sale
|
Direct |
5,737
-45.9%
|
$0
$0.8 P/Share
|
|
Aug 09
2022
|
Dannielle Appelhans CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+50.0%
|
-
|
|
Apr 21
2022
|
David R Epstein Director |
BUY
Open market or private purchase
|
Direct |
30,000
+0.63%
|
$30,000
$1.44 P/Share
|
|
Feb 01
2022
|
Laurence A. Turka Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,517
-33.84%
|
$15,102
$6.57 P/Share
|
|
Feb 01
2022
|
Maiken Keson Brookes CLO & Corp. Secretary |
SELL
Open market or private sale
|
Direct |
2,732
-33.83%
|
$16,392
$6.57 P/Share
|
|
Feb 01
2022
|
Pablo J Cagnoni Director |
SELL
Open market or private sale
|
Direct |
6,730
-15.93%
|
$40,380
$6.57 P/Share
|
|
Jan 29
2022
|
Laurence A. Turka Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,438
+50.0%
|
-
|
|
Jan 29
2022
|
Maiken Keson Brookes CLO & Corp. Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
8,075
+50.0%
|
-
|
|
Jan 29
2022
|
Pablo J Cagnoni Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,250
+33.46%
|
-
|
|
Mar 19
2021
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
210,000
+1.41%
|
$6,090,000
$29.0 P/Share
|
|
Mar 15
2021
|
Maiken Keson Brookes CLO & Corp. Secretary |
SELL
Open market or private sale
|
Direct |
25,000
-100.0%
|
$500,000
$20.24 P/Share
|
|
Mar 15
2021
|
Maiken Keson Brookes CLO & Corp. Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
$175,000
$7.7 P/Share
|
|
Feb 11
2021
|
David R Epstein Director |
SELL
Open market or private sale
|
Direct |
26,704
-0.57%
|
$373,856
$14.93 P/Share
|
|
Feb 10
2021
|
David R Epstein Director |
SELL
Open market or private sale
|
Direct |
7,404
-0.16%
|
$103,656
$14.79 P/Share
|
|
Feb 09
2021
|
David R Epstein Director |
SELL
Open market or private sale
|
Direct |
2,100
-0.04%
|
$29,400
$14.83 P/Share
|
|
Feb 08
2021
|
David R Epstein Director |
SELL
Open market or private sale
|
Direct |
89,233
-1.85%
|
$1,249,262
$14.88 P/Share
|
|
Jul 20
2018
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
33,296,526
+29.91%
|
-
|